capivasertib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Serine/threonine-protein kinase AKT.
- Target
- Serine/threonine-protein kinase AKT
- Mechanism
- Serine/threonine-protein kinase AKT inhibitor
biotech · PIK3CA Mutation · PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation · RLAY
Relay Therapeutics
Relay Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2016 Founded
211 Employees
Public company Type
RLAY · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2016
- Employees
- 211
- Programs
- 6
- Drugs
- 7
- Patents
- 12
Relay Therapeutics pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Relay Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
Development asset linked to Relay Therapeutics in public FDA and regional records.
-
Development asset linked to Relay Therapeutics in public FDA and regional records.
-
Development asset linked to Relay Therapeutics in public FDA and regional records.
-
Development asset linked to Relay Therapeutics in public FDA and regional records.